Kornimate/medical-research-clean huggingface dataset:
socio-clinical factors associated with self-management in parkinson's disease

Conditions: Parkinson Disease

Summary: self-management focuses on the behaviors that people with chronic disease use in order to maintain and improve their health and well-being and includes aspects such as medical and lifestyle management. parkinson's disease (pd) is a chronic, progressive, incurable neurodegenerative disorder that affects motor and non-motor function. engagement in self-management behaviors and high activation may be effective tools in fighting the long-lasting burden of the disease. the goal of the current study was to explore socio-clinical factors that associate with specific self-management behaviors and patient activation among patients with parkinson's disease. pwp were recruited from the movement disorders institute, department of neurology, rambam health care campus. eligible patients were assessed for cognitive status and filled questionnaires regarding socio-clinical factors included age, gender, severity of motor and non -motor symptoms, family and social support. data about the comorbidities were retrieved from electronic medical records

n parkinson's disease (pd), implementation of self-management strategies together with high patient activation may be an effective tool in fighting the long-lasting burden of the disease, but little is known about its determinant. the aims of this study, conducted among patients with pd are to (1) test the association between socio-clinical factors that includes age, gender, cognitive status, comorbidities, disease severity (motor and non-motor symptoms) and social support and smbs including utilization of rehabilitative treatments (an aspect of medical management), physical activity (an aspects of lifestyle management), and patient activation, and (2) to develop predictive model for each of these three aspects of smb, based on socio-clinical factors that includes age, gender, cognitive status, comorbidities, disease severity (motor and non-motor symptoms) and social support. a cross-sectional study of 100 patients that attend a movement disorder clinic with pd will be conducted. participation will include one evaluation session of approximately 90 minutes. information about socio-clinical characteristics and self-management behaviors will be collected using demographic questionnaires, standard questionnaires and from electronic medical records. regression model will test the association between sociodemographic characteristics and self-management behaviors and patient activation.

Eligibility criteria:
inclusion criteria: * diagnosis of pd * age \> 18 exclusion criteria: • mini mental state exam\<20
mri in assessing hypoxia in patients with localized prostate cancer undergoing stereotactic body radiation therapy

Conditions: Prostate Cancer

Summary: rationale: diagnostic procedures, such as mri, may help measure oxygen levels in tumor cells. it may also help doctors predict a patient's response to treatment and help plan the best treatment. purpose: this clinical trial is studying how well mri works in assessing hypoxia in patients with localized prostate cancer undergoing stereotactic body radiation therapy.

objectives: * to characterize the status of global hypoxia within the prostate before stereotactic body radiotherapy (sbrt) as assessed by blood-oxygen-level-dependent and tissue-oxygen-level-dependent mri. * to characterize tumor vasculature and metabolism within the prostate before sbrt as assessed by dynamic contrast-enhanced mri and magnetic resonance spectroscopic imaging, respectively. * correlate prostate and normal tissue hypoxia before sbrt with clinical outcomes (toxicity and biochemical \[psa\] control) after sbrt. outline: within 1-3 weeks before beginning stereotactic body radiotherapy, patients undergo t2-weighted anatomic mri, magnetic resonance spectroscopic imaging, blood-oxygen-level-dependent and tissue-oxygen-level-dependent mri, and dynamic contrast-enhanced mri.

Eligibility criteria:
disease characteristics: * biopsy proven adenocarcinoma of the prostate * localized disease * scheduled to undergo treatment with stereotactic body radiotherapy (sbrt) on a phase ii clinical trial * has not yet started sbrt patient characteristics: * serum creatinine ≤ 1.2 mg/dl * no claustrophobia * no other contraindication to mri (e.g., implanted pacemaker device) * no known allergy to mri contrast prior concurrent therapy: * no prior treatment for prostate cancer (e.g., hormonal therapy or chemotherapy)

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
galvanic vestibular stimulation and motor training in traumatic brain injury survivors

Conditions: TBI; Attention Deficits; Motor Impairments

Summary: the overall goal of the proposed project is to perform a preliminary study to assess the potential effects of galvanic vestibular stimulation (gvs) on the outcomes of a cognitive test of attention and the outcomes of robot-assisted upper-limb rehabilitation.

we plan to explore the use of gvs on the severity of attention span deficits and motor training delivered using a spring-based robot. we intend to carry out the study in a small cohort of traumatic brain injury (tbi) survivors (20 subjects). subjects with attention span deficits but no significant motor impairments will solely undergo a cognitive test of attention with/without gvs. subjects with both attention span deficits and significant motor impairments will undergo a cognitive test of attention and robot-assisted upper-limb rehabilitation with/without gvs.

Eligibility criteria:
inclusion criteria: * moderate to severe traumatic brain injury involving cognitive and/or motor deficits. * neurological injury \>1 year prior to study enrollment * significant attention deficit * for subjects with motor deficits (arms 2 and 3), sufficient voluntary movement and range of motion in the most-affected upper extremity to use the robotic arm system (armeo spring) exclusion criteria: * pregnancy * history of seizures within 6 months of study enrollment * major depression * cognitive impairment that may interfere with understanding instructions * severe limitations of upper extremity range of motion * agitation * other major neurological or psychiatric diseases * participation in other forms of therapy/ intervention for upper extremity motor recovery * end-stage liver, kidney, cardiac or pulmonary disease * a terminal medical diagnosis with survival \<1 year * history of drug or alcohol abuse in the last 3 years * adjustment of, or plan to adjust, psychoactive medications within the preceding 1 month, or within the study period. * current participation in another interventional trial targeting tbi * previous gvs treatment * contraindications to gvs such as implants

Keywords: tbi attention deficits upper extremity weakness
multicpr: the influence of firefighter's ppe on chest compressions (multicpr3)

Conditions: Cardiac Arrest (CA); Occupational Health

Summary: the aim of this clinical study is to evaluate the impact of wearing firefighters' personal protective equipment (ppe) on the quality of chest compressions during simulated resuscitation scenarios. the study compares the effects of one-minute versus two-minute intervals for switching the individual performing compressions. how does the clinical trial work? this randomized cross over trial will be conducted in several locations and will involve a total of 38 fire-fighters. the study will be conducted by the department of anesthesiology of the medical university of vienna. participation in this clinical study is expected to last 30 minutes in total. participants are randomized to either one or two minute intervalls of performing chest compressions in teams of two. after a cooling-of phase of at least 24 hours, they will be switched to the other group. chest compressions will be performed for 12 minutes in full firefighter's ppe. primary outcome will be chest compression depth.


Eligibility criteria:
inclusion: * healthy fire-fighters trained in cpr * cpr training in the last four years * fit and rested exclusion: - pregnant participants
prospective trial for the evaluation of radiogenomics in advanced rectal cancer

Conditions: Rectal Cancer

Summary: in patients with advanced rectal cancer, molecular subtypes will be identified by preoperative biopsy, ct, mri / pet radiomics analysis, clinical features, and clinical features will be confirmed and compared. also, we want to confirm the relationship between these factors and the treatment response after chemoradiotherapy before surgery. the prognosis will be then assessed through 5-year overall survival and 3-year disease free survival. a prospective clinical trial, recruiting 210 persons (approximately 53 per year) that meet the selection criteria for approximately four years from the irb approval date in 2019 (about 53 per year) we will analyze the data and then collect and analyze the data and report the results.


Eligibility criteria:
inclusion criteria: * age: 20-80 years * patients diagnosed with mid-lower rectal cancer and expected to receive chemoradiotherapy before surgery exclusion criteria: * patients with distal metastases confirmed at diagnosis * patients with other bowel diseases such as ibd, ischemic colitis and tb colitis in addition to colorectal cancer * if patients do not agree with this study
jejunoileal vs gastric gist in the era of imatinib.

Conditions: Disease-free Survival; Overall Survival; Recurrence

Summary: introduction: gastrointestinal stromal tumors (gists) located in the jejunum or ileum (ji-gist) are considered of worse prognosis compared to other locations. it has been suggested that this dogma should be revised. the aim of this study is to describe the characteristics of jejunoileal gists and its prognosis; and to compare them with gastric gists in the era of imatinib. patients and methods: we retrospectively reviewed the clinical histories of all the patients diagnosed with gists between january 2000 and november 2016. clinical and pathological data, as well recurrence, metastatic, disease-free survival (dfs) as overall (os) rates of patients with ji-gist or gastric gist (g-gist) were collected and compared.


Eligibility criteria:
inclusion criteria: * any kind of primary mesenchymal tumor of the gastrointestinal tract with a histomorphological and immunohistochemical (cd117 (+) and/or dog1 (+)) profile consistent with gist. exclusion criteria: -

Keywords: gist small bowel jejunum ileum
a study of the evaluation of patients opulation with erectile dysfunction, treated with sildenafil

Conditions: Erectile Dysfunction

Summary: in the present study, it is planned to observe a population of 100 ed patients treated previously with udenafil and for whom their physician decided to switch them to sildenafil because of poor udenafil tolerance and/or poor efficacy.


Eligibility criteria:
inclusion criteria: * male patients aged ≥ 18 years. * clinical diagnosis of erectile dysfunction supported by a total score of less than or equal to 21 according to sexual health inventory-male (shi-m). * patients having a sexual partner throughout the study. * patients having been switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated. the evaluation of udenafil ineffectivness should be performed after attempt intercourse 2 times a week over the course of four weeks. exclusion criteria: * the patients for whom sildenafil is contraindicated according to the local product document (lpd). (see appendix d) * the patients for whom sexual activity is not indicated.

Keywords: erectile dysfunction udenafil sildenafil treatment satisfaction
know your risk: assessment at screening for breast cancer - pilot study

Conditions: Breast Neoplasms

Summary: the purpose of this pilot study is to evaluate a decision support website (realrisks) designed to inform patients about breast cancer chemoprevention. it is coupled with a physician-centered (bnav) decision support website as part of clinical workflow in the primary care setting. the investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting.

breast cancer is the most common malignancy among women in the u.s. and the primary prevention of this disease is a major public health issue. the u.s. preventive services task force and other professional organizations recommend that clinicians discuss chemoprevention with high-risk women. breast cancer chemoprevention with anti-estrogens, such as tamoxifen, raloxifene, exemestane, and anastrozole, is under-utilized, despite several randomized controlled trials demonstrating a 40-65% decrease in breast cancer incidence among high-risk women. compounding this underutilization is the fact that a large proportion of women may be unaware of their high-risk status due to the investigators inability to adequately screen them in the primary care setting. further research is needed to determine how knowledge about breast cancer, actual/perceived risk, and risks/benefits of chemoprevention are best communicated to women in order to promote breast cancer prevention strategies. this study assesses risk communication and shared decision-making in patient-clinician dyads by administering validated measures at baseline, after interacting with the tools prior to the clinic visit, and after the clinical visit (quantitative analysis); and by using observer-based methods of audio-tape recordings of their clinical encounters (qualitative analysis). the investigator hypothesizes that combining a patient-centered decision aid with a physician-centered decision support tool integrated into clinic workflow will improve accuracy of breast cancer risk perception, facilitate referrals for specialized risk counseling, and increase chemoprevention uptake.

Eligibility criteria:
inclusion criteria: * 5-year breast risk of 1.67% or lifetime risk of 20% according to the gail model * the participant understands and is willing to provide informed consent in english or spanish * has a primary care provider at columbia university medical center (cumc) / new york-presbyterian hospital exclusion criteria: * prior use of a selective estrogen receptor modulator (serm) or aromatase inhibitor (ai) for chemoprevention * prior history of breast cancer

Keywords: breast cancer prevention risk assessment chemoprevention decision making
pravastatin for hyperlipidaemia in hiv.

Conditions: HIV Infections; Lipid Metabolism; Glucose Metabolism; Metabolic Abnormality; Lipodystrophy; Cardiovascular Disease

Summary: this study is a randomised, placebo-controlled study of the effect of treatment with the hmg-coa reductase inhibitor, pravastatin, in hiv-infected, protease inhibitor treated patients with high serum cholesterol. we hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.

high serum cholesterol concentrations are commonly seen in hiv-infected patients treated with some protease inhibitor medications as part of long-term antiretroviral therapy for hiv. there is concern that these elevations in cholesterol may negatively impact on long-term risk of cardiovascular disease in this patient population. pravastatin, a hmg-coa reductase inhibitor, is commonly used to treat hypercholesterolaemia in the general population. we aim to examine the effect of 12 weeks therapy with 40mg pravastatin daily in conjunction with dietary advice in hiv-infected patients with elevated serum cholesterol on continued protease inhibitor therapy. after 4 weeks of dietary advice, patients will be randomised to receive either pravastatin or placebo for 12 weeks. assessments include fasting lipid and glycaemic parameters, measures of body composition and hiv disease, and surrogate markers for cardiovascular disease. although previous small studies of pravastatin in this field have been performed, none has done so in a randomised placebo controlled trial taking into account all the relevant measures.

Eligibility criteria:
inclusion criteria: * provide written informed consent to participate in the trial * hiv-1 sero-positive * male/female \>18 years age * currently receiving hiv protease inhibitor therapy for \> 12 weeks and unlikely to require change in existing regimen during the 16 week study period * fasting cholesterol \> 6.5 mmol/l (mean of 2 samples collected \> 3 days apart) exclusion criteria: * any condition which may interfere with ability to comply with study * gastrointestinal disorder which may affect drug absorption * hypertension or congestive cardiac failure * lactic acidemia (serum lactate level \>2.2 mmol/l) * any serious medical condition which may compromise the patient's safety, including pancreatitis or hepatitis within past 6 months * active aids defining conditions * concurrent therapy with any other lipid lowering agents, oral hypoglycaemics, anabolic steroids or insulin

Keywords: hyperlipidaemia lipid metabolism glucose metabolism hmg coa reductase inhibitors lipodystrophy cardiovascular disease treatment experienced hiv
rapid diagnostics for genetic disorders in neonates

Conditions: Acid Base Disorder

Summary: the goal of this study is to test a prototype genomic blood analysis for identifying rare diseases in infants hospitalized in the neonatal intensive care unit (nicu). the main question it aims to answer is: does the prototype accurately identify genetic variation(s) associated with an infant's health condition? researchers will compare the prototype's gene identification to traditional genome sequencing methods of gene identification. participants will be asked to provide a very small (one-tenth of a teaspoon) sample of blood, one-time.


Eligibility criteria:
inclusion criteria: neonates of any gestational age. * abnormality in routine neonatal screening test. * unexplained neonatal hypotonia or neonate-onset seizures. * unexplained and abnormal biochemical laboratory findings. * skeletal dysplasia or joint problems. exclusion criteria: * parental refusal of consent to participate. * provider refusal. * any condition that, in the opinion of the investigator, would interfere with interpretation of study results.
parental attitude toward children dental treatment during covid-19 pandemic

Conditions: Dental Diseases

Summary: the aim of this study is assessment of parental attitude toward children dental treatment and care during covid 19- crisis

the recent spread of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) and its associated coronavirus disease has gripped the entire international community and caused widespread public health concerns. many countries all over the world including egypt, have followed guidelines of limiting dental treatment for emergency cases only. however, as social distancing guidelines are starting to relax across many countries nowadays , dental offices start to reopen for elective procedures , many parents may still have a great concern regarding their children dental treatment during this pandemic. so the aim was to assess their attitude regarding their children dental visit

Eligibility criteria:
inclusion criteria: * egyptian parents living in egypt having children less than 16 years old exclusion criteria: * incomplete questionnaire

Keywords: covid -19 dental treatment dental care parental attitude
eh301 for the treatment of als

Conditions: Amyotrophic Lateral Sclerosis

Summary: the objective of this trial is to evaluate the efficacy and tolerability of eh301 in patients with amyotrophic lateral sclerosis. patients with als are randomized to receive either eh301 or placebo daily and undergo active evaluation for 6 months.


Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosis of probable or definite (sporadic or familial) als by el escorial criteria * onset of symptomatology for more than 6 months * if female: not lactating; negative pregnancy test; agree to use an effective method of birth control throughout study exclusion criteria: * tracheostomy, invasive ventilation, or non-invasive positive pressure ventilation * gastrostomy * evidence of major psychiatric disorder or clinically evident dementia * diagnosis of a neurodegenerative disease in addition to als * current medication apart from riluzole that in the opinion of the investigator would make the patient unsuitable for study participation * recent history (within the previous 6 months) or current evidence of alcohol or drug abuse * concurrent unstable disease involving any system (e.g. carcinoma other than basal cell carcinoma), any cardiac dysrhythmia, myocardial infarction, clinical or ecg signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of coronary artery disease, or any other condition that in the opinion of the investigator would make the patient unsuitable for study participation * baseline qtc (bazett) \> 450 msec for males and \> 470 msec for females * known hepatitis b/c or hiv positive serology * renal impairment defined as blood creatinine \> 2x uln * hepatic impairment and/or liver enzymes (alt or ast) \> 3x uln * hemostasis disorders or current treatment with oral anticoagulants * participated in any other investigational drug or therapy study with a non-approved medication, within the previous 3 months * no medical insurance
parentlink: better and safer emergency care for children

Conditions: Otitis Media; Urinary Tract Infection; Asthma; Head Injury

Summary: the emergency department (ed) constitutes a high-risk environment for errors and poor quality of care. pediatric patients are at increased risk of medical errors. we postulate that implementation of a patient-centered health information technology - parentlink - can address system-level deficiencies and the unique "just-in-time" information needs of ed physicians and the parents of ill children. the proposed work delivers an innovative product - an electronic interface linked to a pediatric knowledge base that integrates parent-derived data with best practices for safe and effective emergency care across common pediatric disease conditions: otitis media, urinary tract infections, asthma, and head trauma. the study has two aims, the first of which addresses critical gaps in data capture: to evaluate the completeness and accuracy of information on symptoms, disease condition, medications and allergies generated by parents using parentlink versus information documented by ed physicians and nurses, using structured telephone interviews as a gold standard. the second aim measures the parentlink's impact on ed patient safety and quality, specifically: a) the error rate for ordering and prescribing of medications during ed care, and b) the percent of ed visits that adhere to national evidence-based guidelines. parentlink will be rigorously evaluated in a clinical trial at two diverse ed sites and will use a sequential, non-randomized observational design with two intervention and two control periods to measure the effects of parentlink on data capture and safety and quality of patient care.


Eligibility criteria:
inclusion criteria: * age less than 12 years with head trauma * age less than 12 years with ear pain * ages less than 12 years with concern for uti * 1 year - 12 years with asthma history and respiratory chief complaint * 3 months - 2 years with fever * parent speaks english or spanish * triage status is non-emergent

Keywords: information technology emergency department medication error quality of care patient-centered care